Glasgow, UK-based ILC Therapeutics has successfully completed a fundraise of £2.5 ($3.2) million. The company develops hybrid interferons, a new drug class engineered for improved therapeutic profiles across multiple indications. The money will support the continued pre-clinical development of the company’s two lead assets, Alfacyte and Dermacyte, as they move towards the clinic. The fundraise […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!